| Nov 15 |
Bolt Biotherapeutics Third Quarter 2024 Earnings: Misses Expectations
|
| Nov 13 |
Bolt Biotherapeutics reports Q3 results
|
| Nov 13 |
Bolt Biotherapeutics GAAP EPS of -$0.40, revenue of $1.14M
|
| Nov 12 |
Bolt Biotherapeutics, Inc. (BOLT) Reports Q3 Loss, Tops Revenue Estimates
|
| Nov 12 |
Bolt Biotherapeutics Inc.: Q3 Earnings Snapshot
|
| Nov 12 |
Bolt Biotherapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update
|
| Nov 9 |
Here's Why We're Watching Bolt Biotherapeutics' (NASDAQ:BOLT) Cash Burn Situation
|
| Nov 7 |
Bolt Biotherapeutics Presents Updated Preclinical Data for BDC-4182 and Key Learnings from Phase 1 Dose-Escalation Trial of BDC-1001 at SITC 39th Annual Meeting
|
| Sep 4 |
Bolt Biotherapeutics Announces Changes to its Board of Directors
|
| Aug 28 |
Bolt Biotherapeutics to Participate in Upcoming September Conferences
|
